LRMR NASDAQ
Larimar Therapeutics, Inc.
1W: -2.0%
1M: -24.6%
3M: -34.2%
YTD: -31.1%
1Y: -43.2%
3Y: -18.1%
5Y: -80.3%
$2.39
+0.15 (+6.70%)
Weekly Expected Move ±12.9%
$2
$2
$2
$3
$3
Credit Risk of going bust: higher than 55% of companies Debt: 2.0% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.01 (down 99.6%), Larimar Therapeutics, Inc. would be worth roughly what it owes.
Total debt $5.0M against a stock market value of $248.3M.
Distance to default 4.68 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $2.5M (short-term plus half of long-term), stock volatility 91.6%; Altman Z'' -8.28. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.01 (down 99.6%), Larimar Therapeutics, Inc. would be worth roughly what it owes.
Total debt $5.0M against a stock market value of $248.3M.
Distance to default 4.68 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $2.5M (short-term plus half of long-term), stock volatility 91.6%; Altman Z'' -8.28. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$0.2M
Congress—
ETF Holdings—
Key Statistics
Market Cap$248.3M
52W Range1.915-6.42
Volume1,203,992
Avg Volume1,721,758
Beta0.69
Dividend—
Analyst Ratings
Company Info
CEOCarole S. Ben-Maimon
Employees71
SectorHealthcare
IndustryBiotechnology
IPO Date2014-06-19
Websitelarimartx.com
Three Bala Plaza East
Bala Cynwyd, PA 19004
US
Bala Cynwyd, PA 19004
US
844 511 9056
About Larimar Therapeutics, Inc.
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.
Latest News
Larimar (LRMR) Loses 22.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Larimar Therapeutics appoints John Harlow as COO
5 Small Drug Stocks Poised to Benefit From a Biotech Recovery
Bank of New York Mellon Corp Takes Position in Larimar Therapeutics, Inc. $LRMR
BlackRock Inc. Buys New Position in Larimar Therapeutics, Inc. $LRMR
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Harlow John B. Jr. | A-Award | 50,000 | — | 2026-09-29 |
| Harlow John B. Jr. | A-Award | 800,000 | $3.14 | 2026-09-29 |
| Harlow John B. Jr. | 0 | — | 2026-09-29 | |
| Hamilton Thomas Edwa | P-Purchase | 50,000 | $3.34 | 2026-07-06 |
| Hamilton Thomas Edwa | A-Award | 55,150 | $3.33 | 2026-05-19 |